COMP <GO>
ARXS vs TMO // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Arxis Inc. (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: ARXS 5
— TMO 9
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: TMO
LAST: $50.82 (-7.48%) • MKT CAP: $23.66B
options-implied-move
7.10%
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
options-implied-move
6.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARXS VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARXS | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 47.40% | 41.00% | +6.40 | ARXS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.00% | 9.30% | -5.30 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 77.1x | 30.4x | +46.70 | TMO | /valuation <GO> |
| Free Cash Flow Yield | 0.76% | 2.40% | -1.64 | TMO | /fcf-yield <GO> |
| Operating Margin | 17.40% | 17.40% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | 2.90% | 15.10% | -12.20 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 114.10% | 3.90% | +110.20 | ARXS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.58 | 4.50 | +0.08 | ARXS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | ARXS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 7.10% | 6.70% | +0.40 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.0 | 59.1 | -11.20 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 0.94 | +0.12 | ARXS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 36.3x | +103.70 | TMO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $23.66B | $262.22B | -$238.56B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARXS REV | TMO REV | ARXS GROSS % | TMO GROSS % | ARXS FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.59B | $44.56B | 47.4% | 44.0% | $179.6M | $6.29B |
| FY 2024 | $743.0M | $42.88B | 44.6% | 44.0% | $37.5M | $7.27B |
| FY 2023 | $424.5M | $42.86B | 44.0% | 44.0% | -$27.0M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARXS // BETA 1.06
TMO // BETA 0.94